In patients with metastatic prostate cancer, ADT is usually given continuously via orchidectomy or administration of anti-androgens; however, agents such as docetaxel chemotherapy and androgen receptor (AR) inhibitors such as darolutamide are being given alongside ADT earlier in the pathway when patients have hormone-sensitive metastatic disease. This evidence concerns the gene AR and metastatic neoplasm.